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INTRODUCTION
Half to three quarters of the adults aged 18–65 years in the
world have had a headache at least once during the last year
and among those individuals more than 10% have reported
migraine (Jensen and Stovner, 2008; Anonymous, 2011).
The epidemiological profile of headaches including mi-
graine varies in different regions of the world. It is known
that there is lower prevalence of migraine in Africa, Asia,
and the Middle East than in Europe and North America
(Merikangas, 2013; Chawla et al., 2014). A large survey of
chronic pain conducted in 16 European countries and Israel
revealed headache in 15% of all chronic pain patients and
migraine in 7% (Breivik et al., 2006). A similar study in
Latvia showed a higher proportion of chronic headache suf-
ferers (23% of chronic pain patients), but a similar propor-
tion of those with migraine — 6% (Logina et al., 2008).
In general, migraine is one of the most common reasons that
make people seek help in primary care settings (Buse et al.,
2012). According to the World Health Organization Global
Burden of Disease Study, migraine is the third most preva-
lent disorder and the seventh most disabling medical disor-
der worldwide (Anonymous, 2013; Lipton and Silberstein,
2015). It significantly restricts the patients’ physical activity
and working capacity, and reduces the patient’s ability to
form social contacts. It is found that men suffering from mi-
graine require on average 3.8 bed-days per year, whereas
women — 5.6 bed-days per year (Chawla et al., 2014),
causing economic damage to the employer as well as the
entire economy of the state. This raises a great need for
studies to further understand the features and mechanisms
of migraine, and to find ways to treat and to prevent disabil-
ity from migraine.
Migraine is a primary headache disorder characterised by
attacks of moderate to severe headache that are typically
unilateral with pulsating quality, aggravated by physical ac-
tivity and associated with nausea, photophobia or phono-
phobia (Goadsby et al., 2002). Two major subtypes of
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ertheless, too many sufferers have frequent and persistent headache attacks that require further
investigation.
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migraine have been recognised by the International Classifi-
cation of Headache Disorders (Anonymous, 2013): 1.1. Mi-
graine without aura — a clinical syndrome of headache with
specific features and associated symptoms, and 1.2. Mi-
graine with aura — primarily characterised by transient fo-
cal neurological symptoms that usually precede or some-
times accompany the headache. The most common visual
aura is flashing lights or loss of vision, but it may be in the
form of pins and needles or other sensory, motor or speech
disturbances, which can last from 5 to 60 minutes (Buse et
al., 2012; Anonymous, 2013). Migraine can begin at any
age, but most often it occurs between 25–55 years. About
6% of men and 18% of women in the US suffer from mi-
graine attacks Lipton et al., 2002).
Migraine mechanisms are various. It is considered to be a
neurovascular disorder, but the cortex-enhanced response
and the release of neurotransmitters, which leads to the acti-
vation of trigeminal conduction pathway, has also been in-
volved. That promotes cerebral vascular dilation and neuro-
genic inflammation in primary neuron terminals localised in
cerebral vascular walls, brain membranes and nasal cavities
(Jones et al., 2012). The underlying triggering pathophysi-
ology of migraine with aura is thought to be a decrease of
circulating blood (Rogawski et al., 2012).
Many factors can initiate a pathophysiological mechanism,
and the migraine attack can occur at any given moment. In a
retrospective study of 1207 migraine patients (Kelman,
2007), 75.9% reported at least one migraine attack provoca-
tive factor: stress (79.5%), female hormonal disturbance
(65.1%), not eating (57.3%), weather (53.2%), sleep distur-
bance (4.8%), perfume or odour (43.7%), neck pain
(38.4%), light(s) (38.%), alcohol (37.8%), smoke (35.7%),
sleeping late (32.0%), heat (30.3%), food (26.9%), exercise
(22.1%), and sexual activity (5.2%).
Although the debate on mechanisms of migraine is continu-
ing, several pharmacological anti-migraine treatment op-
tions are available, which significantly improve the pa-
tients’ quality of life. Unfortunately, different treatment
regimes can fail, and among such patients many have begun
to perceive headache as a life-changing disturbance in their
lives, and have lost faith that it is possible for it to change.
The aim of our study was to explore clinical-epidemio-
logical characteristics of migraine in Latvia and the disabil-
ity of migraine patients, to determine optimal options for
care for these patients.
MATERIALS AND METHODS
Migraine sufferers were chosen from three specialized
headache consultancy centres. 258 clinical records of pa-
tients were checked, and out of them — 178 out-patient
clinical cards were selected coded as “G43 Migraine” ac-
cording to International Classification of Diseases or ICD-
10. 62 patients were excluded from the further investiga-
tion: 12 because of possible secondary cause of headache
(head injury, toxic influence, cerebral ischemia), 33 phone
calls were incorrect or not answered, 17 patients refused to
participate in the survey.
In total, 116 patients fulfilled inclusion criteria of the study:
1) The diagnosis of migraine completely corresponded to
proposed criteria by International Classification of Head-
ache Disorders - III (ICHD-III) — at least five headache at-
tacks, lasted 4–72 hours (untreated or unsuccessfully
treated); headache must have had at least two of the follow-
ing characteristics: unilateral location, pulsating quality,
moderate or severe pain intensity, aggravation by or causing
avoidance of routine physical activity (e.g., walking or
climbing stairs), and during the headache the patient must
have had at least one of the following: nausea and/or vomit-
ing, photophobia and phonophobia;
2) No other any primary or secondary headache disorder
registered;
3) No other somatic or neurological disease detected;
4) The respondent’s consent acquired.
The data of all included 116 migraine sufferers were ob-
tained from their clinical cards, and standardized survey of
patients by phone was made during period from 1 Decem-
ber 2014 to 31 January 2015. Questionnaire includes 40
items on patients’ age, education levels, profession, age on
onset of migraine headaches, migraine in their relatives, at-
tack’s character, associated symptoms, pattern, attack dura-
tions, medication history, treatment and it effectiveness.
Maximum pain intensity during attack was self-evaluated
by patients using 0–10 Numeric Rating Scale (NRS) (where
0 being no pain and 10 being the worst pain patients can
imagine) (McCaffery, 1999).
Disability of patients related to migraine was measured by
Migraine Disability Assessment Questionnaire or MIDAS
(Stewart et al.). It is a set of questions on how many days in
the last three months the patient missed work/school,
his/her productivity was reduced, household work was lost
or reduced, and life activities were put on hold because of
their headaches. The total number of days has been scored
as points, and it corresponds to a certain degree of MIDAS
level of disability: grade I — little or no disability (MIDAS
score 0–5 points); grade II — mild disability (MIDAS score
6–10 points); grade III — moderate disability (11–20
points), and grade IV — severe disability (21 and more
points). The test helps to assess not only disability, but also
the disease severity and treatment effectiveness.
Before completing the questionnaire, each respondent re-
ceived an explanation on the study objectives. The ethical
standards and confidentiality of the patients’ information
were guaranteed according to the regulations and permis-
sion of Rîga Stradiòð University Ethics Committee from 27
November 2014.
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Descriptive statistical calculations were made using Micro-
soft Excel 2010 and IBM (International Business Machines
Corporation) SPSS (Statistical Package for the Social Sci-
ences) Statistics for Windows Version 20.0.
RESULTS
Demographic and other characteristics of the studied mi-
graine patients were summarized in Table 1. The majority
of responders who suffered from migraine were female
(88%). Age distribution among them was from 15 to 64
years, and the prevailing group had age 25–34 years (41%).
There is noticeable tendency that the number of patients de-
creased with age, i.e. 17.2% of patients with age 45–54
years, and only 7.6% with age in 55–64 years.
Among those who suffered from migraine, about a half had
a university education (53%), followed by those with secon-
dary (20%) and vocational (17%) education, and only 2.6%
of patients had finished basic school.
Half (53%) of patients had an occupation related to commu-
nication with people, followed by people involved in a job
with intensive use of a computer (19%) and those employed
in manual labour (12%).
The diagnosis of migraine without aura was confirmed in 56
(48.3%) of the 116 patients and migraine with aura in 58
(50%), and in the remaining two patients probable migraine
was diagnosed. More than a half of the respondents (55.7%)
had one or more relatives suffering from migraine.
In most patients (66 or 57%) headaches started at the age of
15–24, for 17% the attacks began earlier, but in only seven
(6%), migraines started after the age of 35. An oncoming
migraine attack or prodrome was not felt by 67.2% of the
observed (78 of 116), but some of them had some unspe-
cific sensation: tiredness or weakness (21 or 18%), nausea,
excitation or other symptoms (14 or 12.5%).
Usually, a headache attack was provoked by stress (68 or
58.6%), fatigue (38 or 32.8%, sleep disturbances (26 or
22.4%) and female hormonal disturbances (29, or 25%, of
102 women). Less common provocative factors included
weather changes (13 or 11.2%), strong odour (16 or 13.8%),
and certain kinds of food (12 or 10.3%). Only 16 of 116
(13.8%) did not associate their headaches with a provoca-
tion.
In 20 of 116 (17.3 %) patients the length of migraine attack
was less than 12 hours (Fig. 1). Half of the respondents un-
derwent headaches lasting for one (30 patients) and two
(29) days and nights. One-fourth of patients (26) suffered
from prolonged attacks lasting for 49–72 hours, and 10%
(11) for more than 72 hours. Headaches were quite frequent
in half of respondents: 4–8 times a month or more in 26
(22.4%), 34 patients had migraine 2–4 times per month
(29.3%), 42 (36.2%) — 1–2 times per month, but only 13
(11%) had headaches less often (Fig. 2).
T a b l e 1
CHARACTERISTICS OF MIGRAINE PATIENTS
Number of patients, (% of group)
Total Migraine without aura Migraine with aura Probable migraine
Gender, including: 116 56 (48.3%) 58 (50%) 2 (1.7%)
women 102 (87.9%) 50 (43.1%) 51 (44%) 1 (0.9%)
men 14 (12.1%) 6 (5.2%) 7 (6.0%) 1 (0.9%)
Age:
15–24 years 17 (14.7%) 5 (4.3%) 12 (10.3%) 0
25–34 years 48 (41.4%) 23(19.8%) 24 (20.7%) 1 (0.9%)
35–44 years 24 (20.7%) 14 (12.1%) 9 (7.8%) 1 (0.9%)
5–54 years 18 (15.5 %) 9 (7.8%) 9 (7.8%) 0
55–64 years 9 (7.8%) 5 (4.3%) 4 (3.4%) 0
Education :
higher education 61 (52.6%) 27 (23.3%) 34 (29.3%) 0
incomplete higher education 9 (7.8%) 5 (4.3%) 3 (2.6%) 1 (0.9%)
secondary education 23 (19.8%) 9 (7.8%) 14 (12.1%) 0
vocational education 20 (17.2%) 13 (11.2,%) 6 (5.2%) 1 (0.9%)
elementary education 3 (2.6%) 2 (1.7%) 1 (0.9%) 0
Occupation profile:
unemployed 8 (6.9%) 5 (4.3%) 3 (2.6%) 0
student 10 (8.6%) 3 (2.6%) 7 (6.0%) 0
related to communication with people 62 (53.4%) 32 (27.6%) 27 (23.3%) 2 (1.7%)
job with intensive use of computer 22 (19.0%) 8 (6.9%) 14 (12.1%) 0
employed in manual labour 14 (12.1%) 7 (6.0%) 7 (6.0%) 0
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Migraine attacks were usually accompanied by nausea
67.2% (78), vomiting 51.7% (60), photophobia 77.6% (90),
and phonophobia 61.2% (71); less common accompanied
symptoms were increased sensitivity to odours 13.8% (16).
Weakness (15 or 12.9%) and fatigue (45 or 38.8%) were the
main causes of discomfort after attack in part of patients. In
patients who had diagnosis of migraine with aura, the phe-
nomena of aura were more often expressed as changes of
vision in 49.1% (57), dizziness in 21.5% ( 25), mild pain in
5.2% (5) and numbness of some parts of the body in 4.3%
(5).
The migraine patients included in this study were suffi-
ciently investigated: with the magnetic resonance investiga-
tion of brain in 56.0% (65 of 116 patients), computed tomo-
graphy — 52.6% (61), duplex sonography of cerebral blood
vessels — 29.3% (34) and electroencephalography in 5.2%
(6).
Most of the patients (50.9% or 59 of 116) had used specific
medicines — selective serotonin 5-HT1-receptor agonists
(triptans) at least several times for treatment of their mi-
graine attacks. Other treatment options were use of non-
steroidal anti-inflammatory drugs (NSAIDs) (41 or 35.3%),
medicines containing acetaminophen (35 or 30.2%), and an-
algin or metamisole (8 or 6.9%). To manage headache, the
patients also tried to fall asleep (30 or 25.9%), to move into
a dark and quiet place (16 or 13.8%) or take a shower (9 or
7.8%).
Analysis of disability and quality of life by MIDAS (mi-
graine disability assessment) showed some association with
migraine profile, characteristic and treatment. Pain intensity
during attack was estimated as 8.5 ± 2.2 by NRS in all pa-
tient groups without significant difference between males
and females — 8.0 ± 1.3 and 7.9 ± 1.5, respectively.
MIDAS disability grade for males was assessed as mild
(MIDAS score 9.1 ± 7.2), but moderate in women (MIDAS
score 13.5 ± 9.5); however, this difference was not statisti-
cally significance (p  0.05) (Table 2). More than one-third
of patients 37.1% (43) reported that, during the headaches,
they were not able to work, and approximately the same
number (40.5% (47) still coped with their daily duties by
taking medication. Both migraine with aura and migraine
without aura had caused moderate degree of disability, but
differences in MIDAS scores in our patients were not sig-
nificant — 14.2 ± 10.4 and 11.6 ± 7.8 (p > 0.05). Patients
from different educational groups noticed a similar quality
of life by MIDAS scores (Fig. 3), but there was a tendency
for patients with higher education to have a higher disability
grade.
Despite different numbers of patients using different treat-
ment regimens, a better quality of life was found in those
Fig. 1. The average duration of migraine attacks (in hours). Columns, % of
patients (n = 116) with different length of migraine attack; n, number of
patients in each frequency group.
Fig. 2. Frequency of migraine attacks among patients. Columns, % of pa-
tients (n = 116); n, number of patients in each frequency group.
T a b l e 2








MIDAS score (mean, SD) 13 ± 9.3 9.1 ± 7.2 13.5 ± 9.5 p = 0.15
NRS score (mean, SD) 8.5 ± 2.2 8.0 ± 1.3 7.9 ± 1.5 p = 0.9
Migraine without aura pts
(n = 42 )
Migraine with aura pts
(n = 54)
MIDAS score (mean, SD) n.a 11.6 ± 7.8 14.2 ± 10.4 p = 0.3
NRS score (mean, SD) n.a 7.8 ± 1.5 8.0 ± 1.4 p = 0.3
MIDAS, Migraine Disability Assessment Questionnaire; NRS, Numeric pain rating scale; SD, standard deviation; pts, patients; n.a, not applicable; p, signifi-
cance level of correlation between gender and pain intensity or disability. No correlations were statistically significant.
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migraine patients who used NSAIDs, selective serotonin 5-
HT1 (5- hydroxytryptamine-1) receptor agonists (triptans)
and tried to fall asleep (Fig. 4); however, this difference was
not significant (p > 0.05).
DISCUSSION
Migraine is one of the most common disorders of the ner-
vous system. Every 10 seconds, someone in the United
States enters an emergency room with a headache or mi-
graine (Anonymous, 2015), and it is acknowledged as the
third most prevalent disorder in the world (Kurth et al.,
2011; Anonymous, 2013). The population of our study was
selected from specialised centres and does not reflect preva-
lence of migraine in our country fully. However, the data
are representative for an analysis of clinical epidemiology
and the influence on patients’ quality of life.
Remarkable female predominance has been shown in many
studies — up to 75% of all experienced migraine (Chawla
et al., 2014) and 88% in our study. Much evidence exists
connecting hormonal fluctuations and migraine (Sacco et
al., 2012), but not all migraines are hormonal. Recent re-
search has found that women may be more susceptible than
men to depression of cortical spreading and brain excitation
that is thought to lead to migraine (Anonymous, 2015). Re-
garding men, some features of their help-seeking behaviour
have been mentioned. Masculinity ideologies emphasise
self-reliance, competitiveness, emotional control, power
over others and cultural stereotypes – men might believe
that they should keep their emotions under control, and that
by extension they should not be emotional when under
stress to not to appear “girlish” (Mansfield et al., 2003;
Smith et al., 2006). That may be the reason why men do not
go to the doctor, offering the false notion that women get
sick more often. It has been shown that men do feel illness
symptoms as women or a little less symptoms than women,
but they tend to ignore them: “minor illness can be fought
off if you don’t give in to it”, “I often ignore symptoms
hoping they will go way” and “I have to be really ill before
I go and see the doctor” (Galdas et al., 2005). Data obtained
in our study partly confirm such suggestions — the pain in-
tensity by NRS in men and women is practically identical
(8.0 ± 1.3 and 7.9 ± 1.5), but the disability grade differs (9.1
± 7.2 and 13.5 ± 9.5 by MIDAS score).
In general, the clinical epidemiological data from our study
on migraine in the Latvian population corresponds to the
Fig. 3. MIDAS score according to level of
patients education. MIDAS, Migraine Dis-
ability Assessment Questionnaire; n, number
of patients in each educational group.
Fig. 4. MIDAS scores according to type of the treatment of acute migraine attack. MIDAS, Migraine Disability Assessment Questionnaire; n, number of pa-
tients in each treatment group; NSAIDs, non-steroidal anti-inflammatory drugs; SSRA, selective serotonin receptor agonists.
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epidemiological findings in other countries — the majority
of the migraine patients are well-educated women of work-
ing age (25–34 years old).
Despite having no consent on a correlation between mi-
graine and level of education, some studies showed a higher
rate of migraine in persons with lower education (Breslau et
al.,1991; Scher et al.,1998) and a lower rate in those with a
lower educational (Buse et al.,2010; Ertas et al., 2012). Of
all the patients included in our study, more than one half
(53%) had a higher education. This might be explained
partly by the selected population from specialised cabinets
where mainly responsible and self-made persons seek help.
Also, higher education is available and popular in Latvia,
where there are 57 higher education institutions and three
branches of foreign universities, and 29 112 students in
2014 from a total population of 2.013 million (Anonîms,
2014).
We observed an unusually high proportion of patients who
suffered from migraine with aura — 50% of those selected
from the specialised headaches out-patient centres. This
study certainty approves the existence of higher disability
(14.2 ± 10.4 MIDAS score) and pain intensity (8.0 ± 1.4) in
migraine with aura, in comparison with migraine without
aura (11.6 ± 7.8 and 7.8 ± 1.5, respectively)
The study shows the need for extensive investigation of pa-
tients, and it is incorrect to assume that migraine is a clini-
cal diagnosis (Chawla et al., 2014) for which there is no
need for additional studies. Usually, visual and other diag-
nostic tests are used to rule out other diseases that could
mimic or co-exist with migraine (differential diagnoses),
and to determine whether there is a clear change in the aura
symptoms or recurrence of migraine with atypical features
(Buse et al., 2012). There are some studies using magnetic
resonance scans that showed association of migraine with a
variety of structural brain lesions in cerebellum, including
clinically silent infarct-like lesions in mid-life (Kurth et al.,
2011; Scher et al., 2009). This suggests that a remote his-
tory of migraine with aura may be a strong risk factor for
brain lesions commonly found in older populations (Scher
et al., 2009).
Almost half of the respondents in our study had used spe-
cific treatment for migraine — selective serotonin 5-HT (5-
hydroxytryptamine) receptor agonists and, to a lesser extent,
other medicines and non-medical activities. This means that
the level of the diagnosis and treatment of migraine is rela-
tively high. However, there was a high proportion of pa-
tients with frequent and persistent migraine attacks, which
requires analysis of the situation for the improvement of pa-
tient education and promotion of their compliance.
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KLÎNISKI EPIDEMIOLOÌISKS MIGRÇNAS RAKSTUROJUMS LATVIJÂ
Migrçna ir hroniska slimîba, kam raksturîgas vidçji vai stipri izteiktas lçkmjveida galvassâpes, visbieþâk vienpusçjas. Slimîbas
epidemioloìiskâ izpçte palîdz precizçt migrçnas pacientu aprûpes uzdevumus un plânot nepiecieðamos resursus. No trîs Galvassâpju
kabinetu datu bâzçm tika atlasîtas pacientu ambulatorâs kartes ar diagnozi G43 „Migrçna” pçc starptautiskâs slimîbu klasifikâcijas
(SSK-10). Tika veikta telefoniska pacientu standartizçta anketçðana, ietverot 40 jautâjumus. Tika iegûti dati par 116 pacientiem, ar lielâko
îpatsvaru vecuma grupâ no 25 lîdz 34 gadiem (41,4%). Minçtajâ pacientu grupâ sievietes prevalçja (87,9%), puse (52,6%) no migrçnas
pacientiem bija ar augstâko izglîtîbu, 53,4% strâdâja, komunicçjot ar cilvçkiem. Diagnoze „Migrçna ar auru” bija izlikta 58 jeb 50%
pacientu. Vairâkumam (56,9%) pacientu galvassâpes sâkâs tipiskajâ vecumâ jeb 15–24 gados. 1/5 daïai (26 jeb 22,4%) lçkmes bija bieþas
(4–8 un vairâkas reizes mçnesî). Galvassâpju epizoþu ilgumi bieþâk bija 13–24 (25,9%) un 25–48 (25,0%) stundas. 50,9% lçkmju kupçðanai
tika lietota specifiskâ terapija, izvçloties selektîvos serotonîna 5-HT(5-hidroksitriptamîna) receptoru agonistus, taèu 35,3% pacientu bija
izvçlçjuðies nesteroîdos pretiekaisuma lîdzekïus un 30,2% — paraceptamolu saturoðus lîdzekïus. Pusei pacientu veikta magnçtiskâ
rezonanse (56,0%) un datortomogrâfija (52,6%). Var secinât, ka migrçnas epidemioloìiskie dati Latvijâ neatðíiras no citu Eiropas valstu
datiem, t.sk. lielâkâ pacientu daïa ir izglîtotas, publiskâ darbâ strâdâjoðas sievietes reproduktîvâ vecumâ. Migrçnas diagnostika un ârstçðana
ir salîdzinoði augstâ lîmenî, taèu liels ir pacientu îpatsvars ar bieþâm un ieilguðâm galvassâpju lçkmçm.
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